monocyte-endothelial cell adhesion, thereby playing a major role in the anti-inflammatory capacity of the lipoprotein. 5 HDL stimulation of eNOS entails sequential activation of Src kinase(s), PI3 kinase, Akt kinase, and Erk1/2 mitogen-activated protein kinase (MAPK), with Akt phosphorylation of Ser1179 of eNOS causing enzyme activation. 6 The HDL/SR-BI tandem also stimulates endothelial cell migration. 7 In endothelium, HDL/SR-BI signaling requires the adapter protein PDZK1, which directly binds to the C-terminus of SR-BI and couples it to Src kinase(s). 8 Signaling by SR-BI also occurs in enterocytes in response to apical exposure to postprandial micelles (PPM), which are involved in the delivery of dietary lipids as triglyceride-rich lipoproteins. PPM cause SR-BI-dependent activation of Erk1/2 and p38MAPK that leads to the trafficking of apolipoprotein (apo) B from the apical region of the cell to basolateral secretory domains, where it participates in triglyceride-rich lipoproteins assembly and secretion. 9 There are 3 primary characteristics of SR-BI required for signal initiation by the receptor: (1) its ability to invoke cholesterol flux; (2) its C-terminal cytoplasmic domain that binds PDZK1; and (3) its C-terminal transmembrane domain (CTTM), which uniquely interacts with PM cholesterol. 10 The molecular basis and functional significance of SR-BI interaction with PM cholesterol are unknown. In the present investigation, we tested the hypotheses that the interaction is required for SR-BI signaling and that it enables SR-BI to serve as a PM cholesterol sensor. The SR-BI CTTM that binds PM cholesterol lacks sequence homology with known cholesterol-binding domains, such as those within the sterolsensing proteins 3-hydroxy-3-methylglutaryl-CoA reductase, sterol regulatory element-binding protein cleavage-activating protein, and Niemann-Pick C1. [11] [12] [13] [14] [15] However, in select cholesterol-binding proteins such as Niemann-Pick C1, glutamine (Q) forms hydrogen bonds with the 3β-hydroxyl group of cholesterol to mediate direct binding, 14, 15 and within the SR-BI CTTM there is a highly conserved glutamine that is lacking in the CTTM of CD36, which does not interact with PM cholesterol 10 (Figure 1 ). We therefore tested the primary hypotheses and their implications by studying a point mutant of SR-BI in which the glutamine at position 445 was substituted by alanine (SR-BI-Q445A; Figure 1B and 1C).
Methods

Cell Culture, Transfection, and Mutagenesis
COS-M6, bovine aortic endothelial cells, and Caco-2/TC7 cells were used as previously described. [8] [9] [10] COS-M6 cells lack endogenous SR-BI, thereby providing a model system in which forms of SR-BI can be expressed for structure-function experiments. 10 Transient transfections were performed using Lipofectamine 2000 (Invitrogen) 6 and, unless otherwise stated, studies were performed 48 hours after transfection. Although transfected receptor is abundant at greater levels than are endogenously expressed, previous studies of mechanisms of SR-BI function in endothelium using this approach yielded parallel findings for endogenous vs exogenous receptor whenever such comparisons were possible. 10 To study the impact of SR-BI vs SR-BI-Q445A in Caco-2/TC7 cells, stable cell lines were created by cotransfection with the puromycin resistance gene-containing pPUR vector (BD Biosciences) and selection with 10 μg/mL puromycin (Sigma-Aldrich); experiments were performed on welldifferentiated cells on semipermeable filters 15 to 20 days after seeding. 9 Relative levels of expression of SR-BI and SR-BI-Q445A were evaluated by real-time quantitative polymerase chain reaction 16 using cyclophilin transcript abundance as an internal control. mSR-BI-Q445A was generated by polymerase chain reaction-based sitedirected mutagenesis (Stratagene) using the entire open reading frame of murine SR-BI in pcDNA 3.1 as template, and resulting sequences were confirmed by DNA sequencing. Figure 1 . Structure of the scavenger receptor class B, type I (SR-BI) C-terminal transmembrane (CTTM) domain and the SR-BI-Q445A point mutant. A, Sequence alignment of amino acids in the CTTM domain of SR-BI homologs (residues 440-461) from mouse (Mus musculus, Mm, Q6100 9, Swiss-Prot), rat (Rattus norvegius, Rr, P97943, Swiss-Prot), human (Homo sapien, Hs, Q8WTUO, Swiss-Prot), Chinese hamster (Cricetulus griseus, Cg, Q60417, Swiss-Prot), rabbit (Oryctolagus cuniculus, Oc, AAP40266.1, Pubmed), pig (Sus scrofa, Ss, Q85QC1, Swiss-Prot), and bovine (Bos Taurus, Bt, O18824, Swiss-Prot). Fully conserved residues are in bold. B, Comparison of murine SR-BI and CD36 CTTM domains. Conserved residues of SR-BI not shared with CD36 are shown in bold. The sequence of the Q445A mutant form of mouse SR-BI is also shown, and the location of the point mutation is highlighted by the box. C, Depiction of the topography of the SR-BI protein on the plasma membrane (PM) and its N-terminus and C-terminus. The open rectangle identifies the CTTM domain (residues 440-461), with the position of Q445 indicated. 
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HDL Preparation
Human HDL prepared by density gradient ultracentrifugation was provided by Drs J. Goldstein and M. Brown, University of Texas Southwestern. 17 The HDL was isolated from healthy volunteers after a 12hour fast, and the HDL 3 subfraction (density range, 1.12-1.2181 g/mL) was obtained and used in all experiments. The HDL was stored at 4°C before use. The concentration used refers to the total protein concentration, with the majority of HDL protein being apoA-I.
Assessments of Intracellular and Global Cholesterol Homeostasis
Cell HDL binding, cholesterol efflux and selective uptake, and SR-BI PM cholesterol binding were evaluated using previously described methods. 10, 18 In mice, plasma total cholesterol was measured enzymatically, and lipoprotein analysis was performed using fast protein liquid chromatography gel filtration and quantification of fraction cholesterol content. 19
Protein Abundance and Interaction
Cell fractionation to assess SR-BI subcellular localization, immunoblot analyses including for the evaluation of eNOS, c-Src, and p38MAPK phosphorylation, and coimmunoprecipitations to evaluate interaction between SR-BI and hemagglutinin-tagged PDZK1 (PDZK1 HA ) or c-Src were performed as described. 6, 8, 9, 20 
eNOS Activation and Cell Migration Assays
Radiolabeled arginine-to-citrulline conversion by intact cells and scratch assays were performed as previously reported. 7
Adenovirus Generation and Administration
Recombinant adenoviruses were constructed by in vitro cre/loxPmediated recombination, propagated in 911 cells, purified, and particles per mL were quantified, and the adenoviruses were administered to mice by intravenous injection as outlined previously. [21] [22] [23] [24] These and all other in vivo procedures were approved by the Institutional Animal Care and Use Committees.
Macrophage RCT
In vivo measurement of macrophage RCT was conducted in mice using 3 H-cholesterol-labeled foam cells as previously reported. 25
Immunofluorescence and Confocal Microscopy
Immunofluorescence and confocal analyses in enterocytes (Caco-2/ TC7 cells) were performed as described. 9, 26 The PPM used to invoke responses in the enterocytes were lipid micelles with a composition resembling that of human postprandial duodenal micelles. They were prepared as previously described. 9
In Vivo Angiogenesis Assays
The impact of SR-BI vs SR-BI-Q445A on HDL-induced angiogenesis was evaluated in vivo in mice using subcutaneously placed 20-µL silicone cylinders containing matrix and fibroblast growth factor-2. 27, 28 Detailed Methods are provided in the online Supplement.
Results
SR-BI-Q445A and Cellular Cholesterol Homeostasis
The PM targeting of wild-type (WT) SR-BI and SR-BI-Q445A, which is necessary for the receptor to mediate cholesterol and phospholipid flux, was compared in transfected COS-M6 cells by subfractionation and immunoblot analysis ( Figure  2A ). Quantification of receptor abundance in PM relative to postnuclear supernatant revealed that SR-BI-Q445A localization to PM was similar to that of the WT receptor. The functions of WT SR-BI and SR-BI-Q445A in cellular cholesterol homeostasis were tested in transfected COS-M6 cells. WT SR-BI and SR-BI-Q445A displayed similar HDL binding ( Figure 2B ), selective HDL cholesteryl esters uptake ( Figure 2C ), selective uptake efficiency ( Figure 2D ), and cholesterol efflux to HDL ( Figure 2E ). In contrast, compared with WT SR-BI, photocholesterol binding to SR-BI-Q445A was decreased by 71% ( Figure 2F ). Thus, SR-BI-Q445A has normal targeting to PM, HDL particle binding, and cholesterol efflux and selective uptake efficiency, but has attenuated interaction with PM cholesterol.
SR-BI-PM Cholesterol Interaction and PDZK1
Direct SR-BI interaction with PDZK1 via its cytoplasmic C-terminal tail is required for SR-BI-initiated signal transduction. 10, 29 To determine whether SR-BI interaction with PM cholesterol influences receptor protein-protein interaction with PDZK1, coimmunoprecipitation was performed in COS-M6 cells expressing either WT SR-BI or SR-BI-Q445A and C-terminally HA-tagged PDZK1 (PDZK1 HA ). In cells expressing WT SR-BI and PDZK1 HA , antibody to hemagglutinin yielded coimmunoprecipitation of SR-BI (Online Figure  IA) , and antibody to SR-BI yielded coimmunoprecipitation of PDZK1 HA (Online Figure IB) . Similarly, in cells expressing SR-BI-Q445A and PDZK1 HA , antibody to hemagglutinin yielded coimmunoprecipitation of SR-BI-Q445A (Online Figure IC) , and antibody to SR-BI yielded coimmunoprecipitation of PDZK1 HA (Online Figure ID) . Thus, the interaction of PM cholesterol with SR-BI does not influence receptor interaction with PDZK1.
SR-BI-PM Cholesterol Interaction and Receptor Signaling
Because SR-BI-Q445A has attenuated interaction with PM cholesterol but normal capacity to bind HDL, to mediate cholesterol flux, and to interact with PDZK1, the mutant allows discrete determination of the role of PM cholesterol interaction in signaling by the receptor. We evaluated HDL-mediated activation of eNOS in transfected COS-M6 cells, which provides a robust means to detect amplified downstream processes. As seen previously, 4 eNOS activity was increased 2-fold by HDL in cells coexpressing WT SR-BI and eNOS ( Figure  3A ). However, eNOS activation by HDL did not occur in cells expressing SR-BI-Q445A. Similarly, treatment of WT SR-BI-expressing cells with HDL caused eNOS Ser1179 phosphorylation ( Figure 3B and 3C), whereas it did not occur in SR-BI-Q445A-expressing cells.
Because the most proximal signaling event known to be initiated by HDL/SR-BI is Src kinase activation, 6 we determined whether SR-BI-Q445A initiates HDL-induced Src Tyr419 phosphorylation. Whereas WT SR-BI invoked Src phosphorylation in response to HDL ( Figure 3D and 3E), SR-BI-Q445A did not. We further determined whether the interaction of SR-BI with Src is altered by the Q445A mutation by coimmunoprecipitation. WT SR-BI and SR-BI-Q445A displayed comparable interaction with Src (Online Figure IE) . Thus, although the capacity to bind PM cholesterol does not influence the interaction between Src and SR-BI, it is required for SR-BI to initiate signaling in response to HDL.
SR-BI-PM Cholesterol Interaction and Cholesterol Sensing
We previously demonstrated that cholesterol-free methyl-βcyclodextrin (CD) activates signaling in an SR-BI-dependent manner. 10 Because CD removes PM cholesterol and does not require cell surface receptors to serve as a cholesterol acceptor, 30 this previous observation suggests that SR-BI may be a PM cholesterol sensor. To characterize this further, signaling to eNOS on manipulation of cholesterol flux with CD was evaluated in COS-M6 cells expressing the enzyme and WT SR-BI. Whereas cholesterol-free CD stimulated eNOS, cholesterol-containing CD did not ( Figure 4A ), and both HDL and cholesterol-free CD activation of eNOS were prevented by the Src kinase inhibitor PP2 ( Figure 4B ). We then used SR-BI-Q445A to determine whether SR-BI interaction with PM cholesterol is required for signaling in response to cholesterol efflux to CD ( Figure 4C ). Whereas both HDL-stimulated and CD-stimulated eNOS activation occurred in cells expressing WT receptor, neither occurred in SR-BI-Q445A-expressing cells. Thus, the interaction of SR-BI with PM cholesterol is required for the receptor to initiate signaling in response to cholesterol movement.
SR-BI PM Cholesterol Sensing and Hepatic Receptor Function
To determine the role of PM cholesterol sensing by SR-BI in the function of the receptor in liver, adenoviral constructs were created harboring WT SR-BI (AdSR-BI) or SR-BI-Q445A (AdSR-BI-Q445A). Male C57BL/6 mice were injected with empty control adenovirus (AdNull) or AdSR-BI or AdSR-BI-Q445A and were allowed to recover. AdSR-BI or AdSR-BI-Q445A injection resulted 7 days later in a 6-fold increase in hepatic SR-BI protein expression (Online Figure IIA) . In mice injected with AdSR-BI, plasma total cholesterol was decreased by 68% on day 3 compared with levels in mice receiving AdNull (Online Figure IIB) , mirroring previous observations. 21, 31 Total cholesterol was similarly lowered by 69% on day 3 in mice injected with AdSR-BI-Q445A. By day 7, total cholesterol increased in both AdSR-BI-injected and Ad-SR-BI-Q445Ainjected mice to levels similar to those in control mice. Fast performance liquid chromatography analysis of lipoproteins in mice injected with AdSR-BI revealed reduced HDL cholesterol on day 3, with persistently low HDL cholesterol on day 7 accompanied by an increase in very-low-density lipoprotein cholesterol (Online Figure IIC , left). This mimicks previous findings. 21, 31 Similarly, mice receiving AdSR-BI-Q445A displayed lower HDL cholesterol on day 3 and day 7, with an increase in very-low-density lipoprotein cholesterol levels on day 7 (Online Figure IIC, right) .
To directly measure how PM cholesterol sensing by SR-BI in the liver influences RCT, in vivo measurements of macrophage RCT were performed after intravenous injection of AdNull, AdSR-BI, or AdSR-BI-Q445A in male mice. Measurements of plasma 3 H-cholesterol recovery revealed a progressive increase in plasma 3 H-cholesterol in AdNullinjected mice (Online Figure IIIA) ; in contrast, AdSR-BI and AdSR-BI-Q445A injection markedly lowered 3 H-cholesterol recovery in the plasma to a similar degree. Liver 3 H-cholesterol recovery, biliary 3 H-cholesterol and 3 H-bile acid secretion, and 3 H-cholesterol recovery in the feces were equally increased by liver overexpression of WT SR-BI or SR-BI-Q445A (Online Figure IIIB-IIIE, respectively) . Thus, cholesterol transfer from macrophages to feces was similar for the 2 forms of receptor.
Taken together, these results indicate that PM cholesterol sensing does not influence the hepatic role of SR-BI in RCT.
SR-BI PM Cholesterol Sensing in Enterocytes
In enterocytes, PPM-induced signaling and apoB trafficking involved in the delivery of dietary lipids as triglyceride-rich lipoproteins are fully prevented by BLT-1, 9 which blocks SR-BI-mediated lipid transfer to and from the receptor's membrane lipid environment. 32, 33 To determine whether SR-BI PM cholesterol sensing occurs in enterocytes, Caco-2/TC7 cells were stably transfected with WT SR-BI or SR-BI-Q445A. Both cell lines expressed abundant exogenous SR-BI (data not shown). On PPM treatment, p38MAPK activation was observed in WT SR-BI-expressing cells, but not in SR-BI-Q445A-expressing cells ( Figure 5A and 5B) . We further analyzed PPM-induced movement of apoB and found that in WT SR-BI transfected cells, apoB trafficks normally to intracellular compartments after PPM supply. 9 However, apoB is maintained in the apical compartment despite PPM application in SR-BI-Q445A-expressing cells ( Figure 5C and 5D) . These findings indicative of a dominant-negative effect of SR-BI-Q445A reveal that SR-BI interaction with PM cholesterol is required for PPM-induced signaling and the functional response of apoB trafficking away from the apical surface in enterocytes.
There is evidence that SR-BI function, particularly in the initiation of intracellular signaling, depends on its localization in PM caveolae/lipid rafts. 4, 34 In enterocytes, PPM exposure causes increased trafficking of SR-BI to caveolae/lipid rafts. 9 Because the basis for PPM-stimulated trafficking of SR-BI to rafts in enterocytes is unknown, the impact of PPM on receptor trafficking was evaluated in WT SR-BI vs SR-BI-Q445Aexpressing cells in sucrose gradient experiments. 9 In SR-BIexpressing cells that received no micelles in the apical medium ( Figure 5E , upper left), there was an abundance of SR-BI in nonraft/high-sucrose density cell fractions (fractions 7, 8) compared with low-sucrose density raft fractions (fractions 4, 5; flotillin-1 serves as marker). In response to the application of PPM, less SR-BI was found in the nonraft fractions and more SR-BI was found in the raft fractions ( Figure 5E , upper right). Summary data for 3 independent experiments revealed that there was a 78% increase in raft-associated SR-BI in response to PPM ( Figure 5F ). In contrast, in SR-BI-Q445Aexpressing enterocytes there was no change in the partitioning of the receptor in response to PPM ( Figure 5E , lower panels, and Figure 5F ). These collective findings indicate that PM cholesterol sensing by SR-BI occurs in enterocytes, and that it is required for enterocyte responses to PPM. In addition, there is a role for PM cholesterol binding in PPM-induced changes in SR-BI abundance in enterocyte rafts.
To further determine whether SR-BI senses cholesterol movement from the PM in enterocytes, additional experiments were performed with CD and cholesterol-containing CD. In cells expressing WT receptor, p38MAPK was activated by both PPM and CD but not by CD cholesterol (Figure 6A and 6B) In parallel, PPM and CD caused equal trafficking of apoB from the apical compartment, whereas CD cholesterol had no effect ( Figure 6C and 6D) . In contrast, neither PPM nor CD activated p38MAPK or invoked apoB trafficking in cells expressing SR-BI-Q445A. Thus, SR-BI interaction with PM cholesterol underlies the capacity of the receptor to recognize alterations in PM cholesterol in enterocytes.
SR-BI PM Cholesterol Sensing in Endothelial Cells
To determine the role of SR-BI PM cholesterol sensing in endothelial cells, bovine aortic endothelial cells were transfected with sham plasmid or cDNA encoding WT SR-BI or SR-BI-Q445A, and responses to HDL were tested 24 or 48 hours later. Equal expression of exogenous receptors was attained ( Figure 7A ). Sham-transfected bovine aortic endothelial cells and cells transfected with WT SR-BI displayed similar eNOS activation by HDL, and comparable stimulation was invoked by the control eNOS agonist vascular endothelial growth factor ( Figure 7B ). In contrast, the introduction of SR-BI-Q445A prevented eNOS activation by HDL, whereas enzyme stimulation by vascular endothelial growth factor was unaffected. Sham-transfected cells and cells transfected with WT receptor displayed migratory responses to HDL and vascular endothelial growth factor that were similar ( Figure 7C and 7D) . In contrast, although vascular endothelial growth factor-induced migration did not change with the introduction of SR-BI-Q445A, there was 72% attenuation of migration activated by HDL.
To determine whether SR-BI PM cholesterol sensing governs endothelial cell behavior in vivo, we established a model system for the study of HDL/SR-BI modulation of angiogenesis in mice that is independent of hepatic or systemic actions of the lipoprotein or its receptor. The model entails subcutaneous placement of matrix and fibroblast growth factor-2 endothelial cell abundance, indicating a robust stimulation of angiogenesis. We then determined that HDL activation of angiogenesis was similar in cylinders containing AdNull vs AdSR-BI (data not shown), indicating that the provision of additional WT receptor does not affect the process. This in vivo finding is identical to what we observed with overexpression of AdSR-BI in cultured endothelial cells ( Figure 7C and 7D). After confirming equal ability to overexpress WT vs mutant receptor in infected endothelial cells ( Figure 7F , inset), the impact of HDL was compared in cylinders into which AdSR-BI or AdSR-BI-Q445A was introduced at the time of matrix preparation. Figure 7E shows 2 examples of cylinders per study group (open at top) with blood-filled microvessels within the matrix, and summary data for endothelial cell density are in Figure 7F . Whereas HDL caused a 4-fold increase in endothelial cell density in the presence of AdSR-BI, the response was decreased by more than half in the presence of AdSR-BI-Q445A. Thus, SR-BI-Q445A had a specific dominant-negative effect on endothelial cell behaviors invoked by HDL both in cell culture and in vivo. As such, SR-BI PM cholesterol sensing is required for the known potential cardiovascular protective actions of HDL in endothelium.
Discussion
In the present studies, the novel capacity of SR-BI to interact with PM cholesterol and its implications on receptor function have been interrogated. We discovered that Q 445 in the SR-BI CTTM is critically involved in the interaction of the receptor with PM cholesterol. Importantly, alanine substitution of Q445 yielded a receptor with normal capacities to bind HDL and to mediate cholesterol flux, and to bind with normal interactions with PDZK1 and Src, which are necessary for intracellular signaling initiated by SR-BI. Having retained these critical features, with SR-BI-Q445A it was possible to demonstrate that the interaction with PM cholesterol is required for HDL-induced signaling by the receptor. Thus, an important new feature of SR-BI enabling it to serve diverse functions has been identified. In previous studies, we observed that in cells devoid of SR-BI intracellular signaling does not occur on treatment with CD, which removes PM cholesterol and does not require cell surface receptors to serve as a cholesterol acceptor 30 ; in contrast, the introduction of SR-BI yields cells that display signaling in response to CD. 10 In the present work, we demonstrate that whereas intracellular signaling occurs with CD treatment of cells expressing WT SR-BI, cells expressing SR-BI-Q445A, which has attenuated interaction with PM cholesterol, are unresponsive. These findings indicate that SR-BI is a PM cholesterol sensor, and that its capacity to interact with PM cholesterol underlies this unique function. SR-BI now joins the list of known sterol-sensing proteins, which includes sterol regulatory element-binding protein cleavage-activating protein, Insig 3-hydroxy-3-methylglutaryl Co-A reductase, liver X receptors, and Niemann-Pick C1 and C2 35 However, in contrast to these known sterol-sensing proteins, SR-BI is the first identified PM cholesterol sensor and the first sterol-sensing protein to regulate kinase signaling.
By overexpressing SR-BI-Q445A in the mouse liver, we found that PM cholesterol sensing is most likely not operative in the role of hepatic SR-BI in global cholesterol homeostasis or in macrophage RCT. This observation indicates that the classical function of SR-BI to mediate cholesterol movement between its ligands and cells is sufficient for the receptor in hepatocytes to participate in RCT. However, in studies of enterocytes, in which SR-BI enables the sensing of PPM involved in the delivery of dietary lipids as triglyceride-rich lipoproteins, 9 using SR-BI-Q445A we discovered that PM cholesterol sensing by the receptor is required for PPMinduced signaling and apoB intracellular movement. We also found that PM cholesterol sensing is necessary for PPM to promote the recruitment of SR-BI to PM caveolae/lipid rafts in enterocytes. In addition, we discovered that PM cholesterol sensing is critically involved in important functions of SR-BI in endothelial cells. In particular, we found that both HDL activation of eNOS that increases the production of the atheroprotective signaling molecule NO 4 and HDL stimulation of endothelial cell migration that is critical to the maintenance of intimal layer integrity 7 require SR-BI PM cholesterol sensing. Moreover, to determine whether SR-BI PM cholesterol sensing governs endothelial cell behavior in vivo, we devised a means to study HDL/SR-BI modulation of angiogenesis in mice that is independent of hepatic or systemic actions of the lipoprotein or its receptor. Using the new model system, we found that PM cholesterol sensing is required for HDLinduced angiogenesis in vivo. Thus, we have shown in 2 different cell types, in response to 2 different lipid complexes (HDL and PPM), in cell culture as well as in mice, that SR-BI PM lipid sensing mediates cellular responses of relevance to cardiovascular and metabolic health and disease. The differences in the impact of the SR-BI-Q445A mutant in enterocytes and endothelium vs in the liver further suggests that the sensing of changes in PM cholesterol is relevant to SR-BI action, particularly in cell types in which an important function of the receptor entails the regulation of intracellular signaling. These functions could potentially be further interrogated in vivo by the creation of an SR-BI-Q445A knock-in mouse.
Evaluations of the actions of HDL on endothelium have received attention recently as potential means to interrogate the functional characteristics of HDL. [36] [37] [38] [39] [40] [41] Differences in HDL function may be more informative than simple assessments of HDL cholesterol abundance in our attempts to better-understand the cardiovascular impact of HDL, to assign cardiovascular disease risk, and to interpret the findings of trials testing HDL-targeted therapies. 42, 43 The model system that we have devised to study HDL-induced angiogenesis in mice in a manner that avoids hepatic or systemic actions of the lipoprotein may provide a valuable means to directly evaluate endothelial cell responses to minute quantities of patient-derived HDL in vivo. As importantly, through genetic manipulation within the 20-µL cylinder or by use of the cylinder in genetically modified mice, the molecular basis for direct actions of HDL on endothelium can be interrogated to a greater depth in vivo.
In addition to its utility in revealing the existence of cholesterol sensing by SR-BI and the functional implications of that sensing in endothelium and enterocytes, further studies of SR-BI-Q445A will allow greater elucidation of the mechanisms that underlie SR-BI signaling. This includes future studies A, Bovine aortic endothelial cells were transfected with sham plasmid or cDNA encoding wild-type (WT) SR-BI or SR-BI-Q445A, and receptor abundance was evaluated 48 hours later by immunoblot analysis. Abundance (left panel) of endogenous SR-BI when the protein load is increased 10-fold. B, In the experimental groups described in (A), NOS activity was evaluated in intact cells by measuring 14 C-L-arginine to 14 C-L-citrulline conversion during 15-minute incubations in the absence (basal) or presence of HDL (50 µg/mL) or vascular endothelial growth factor (VEGF; 100 ng/nL). C and D, In the experimental groups described in (A), endothelial cell migration was evaluated in scratch assays during 24 hours treatments with media alone (basal), HDL (100 µg/mL), or VEGF (100 ng/nL). In B and D, values are mean±SEM, n=4-5. *P<0.05 vs basal; †P<0.05 vs SR-BI. E and F, In vivo evaluation of HDL-induced angiogenesis in matrixcontaining cylinders placed subcutaneously in male C57BL/6 mice. Microvessel ingrowth in response to HDL (100 µg/mL) was compared in cylinders into which AdSR-BI vs AdSR-BI-Q445A was introduced at the time of matrix preparation. E, Two examples of cylinders per study group (opening at top) with blood-filled microvessels within the matrix. F, Summary data for endothelial cell density, expressed relative to density in control-treated cylinders. Values are mean±SEM; n=8 for control cylinders and n=14-16 for HDL-treated cylinders. *P<0.05 vs basal; †P<0.05 vs SR-BI. Inset in (F) shows comparable efficacy of adenovirus-based expression of SR-BI and SR-BI-Q445A in cultured endothelial cells (lanes 1-3 are AdNull, AdSR-BI, and AdSR-BI-Q445A, respectively; upper blot is SR-BI; lower blot is actin).
aimed at determining how the sensing of cholesterol movement causes SR-BI to activate kinases, with the activation of Src kinases being the most proximal known signaling event. 6 The interaction between SR-BI and PM cholesterol may underlie possible conformational changes that occur in the receptor on cholesterol movement, perhaps resulting in dynamic alterations in yet-to-be-discovered interactions between the receptor and other transmembrane or intracellular signaling molecules. The SR-BI-Q445A mutant also provides a means to segregate cellular responses caused specifically by SR-BI-mediated cholesterol or phospholipid movement from those that require SR-BI-mediated signaling. Further study of PM cholesterol sensing by SR-BI will enhance our basic understanding of the role of the receptor in cardiovascular health and disease.
